Target intelligence / Profile preview

Expanded GAA trinucleotide repeat in the frataxin gene

Molecular classification
Other (Trinucleotide repeat expansion, Non-coding repeat mutation)
01

Overview

The expanded GAA repeat in the frataxin gene is a large trinucleotide (GAA) repeat expansion mutation occurring in intron 1 of the FXN gene. In healthy individuals, this repeat is usually fewer than 12–33 units, while in individuals with Friedreich’s ataxia, the repeat expands to 66 up to >1,000 units. This expansion causes gene silencing through heterochromatin formation and other repressive epigenetic mechanisms, leading to severely reduced frataxin expression. Frataxin is essential for mitochondrial function; its deficiency results in neurodegeneration, most prominently manifesting as Friedreich’s ataxia. The expanded repeat does not encode a protein or act as a receptor, enzyme, or transporter, but directly causes disease by pathologically altering gene expression and chromatin state.

Other names
GAA repeat expansion in FXNExpanded GAA repeat in FXNFRDA GAA repeat expansionFriedreich’s ataxia GAA expansion
02

Mechanism of action

Epigenetic modulation: HDAC inhibitors and other agents aim to reverse repeat-induced silencing by promoting chromatin relaxation and restoring frataxin expression.

03

Biological functions

Gene expression regulation (pathologically, as it impedes expression)Epigenetic silencing (abnormal chromatin structure and gene repression)
04

Disease associations

Neurodegenerative disease (Friedreich’s ataxia)
05

Safety considerations

Nonspecific off-target effects of epigenetic therapies (e.g., HDAC inhibitors may broadly affect gene expression)Long-term safety of manipulating chromatin and epigenetic state is unknown
06

Interacting drugs

Histone deacetylase (HDAC) inhibitors (experimental)

2 more in the full profile.

07

Biomarkers

GAA repeat expansion size (for diagnosis, prognosis, and patient selection)Frataxin protein levels (for efficacy monitoring)

Beyond the preview

Go deeper on Expanded GAA trinucleotide repeat in the frataxin gene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Expanded GAA trinucleotide repeat in the frataxin gene.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call